• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . SARS-CoV-2 Variants with T135I Nucleocapsid Mutations may Affect Antigen Test Performance

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Nov 7;S1201-9712(21)00853-5.
doi: 10.1016/j.ijid.2021.11.006. Online ahead of print.
SARS-CoV-2 Variants with T135I Nucleocapsid Mutations may Affect Antigen Test Performance


Ming-Jr Jian[SUP] 1 [/SUP], Hsing-Yi Chung[SUP] 1 [/SUP], Chih-Kai Chang[SUP] 1 [/SUP], Jung-Chung Lin[SUP] 2 [/SUP], Kuo-Ming Yeh[SUP] 2 [/SUP], Chien-Wen Chen[SUP] 3 [/SUP], De-Yu Lin[SUP] 2 [/SUP], Feng-Yee Chang[SUP] 2 [/SUP], Kuo-Sheng Hung[SUP] 4 [/SUP], Cherng-Lih Perng[SUP] 1 [/SUP], Hung-Sheng Shang[SUP] 5 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic. Additionally, several SARS-CoV-2 variants have continuously challenged diagnostic testing due to viral diversity in spike and nucleocapsid (N) protein mutations. SARS-CoV-2-variant proliferation potentially affects N protein-targeted rapid antigen testing. We performed rapid antigen and reverse transcription polymerase chain reaction (RT-PCR) tests simultaneously in patients with suspected coronavirus disease 2019 (COVID-19). To determine the N protein variations, direct whole-genome sequencing was performed, and the viral assemblies were uploaded to GISAID. We compared their genomes with those of global virus strains from GISAID. These isolates belonged to the B.1.1.7 variant, exhibiting several amino acid substitutions, including D3L, R203K, G204R, and S235F N protein mutations. We also identified the T135I mutation in one variant case in which rapid antigen and RT-PCR tests were discordantly negative and positive, respectively. Our findings suggest that the variants undetected by the Panbio[SUP]TM[/SUP] COVID-19 rapid antigen test may be due to N-protein T135I mutations, posing a potential diagnostic risk to commercially available antigen tests. Hence, we recommend concomitant paired rapid antigen tests and molecular diagnostic methods to detect SARS-CoV-2. False-negative results could be rapidly corrected using confirmatory RT-PCR results to prevent future COVID-19 outbreaks.

Keywords: B.1.1.7 variant; COVID-19; N protein; SARS-CoV-2; rapid antigen test.
 
Back
Top Bottom